Category Archives: leadership

Some Content on Content Marketing

by Al Topin Do I have the only e-mail inbox clogged with more and more content about content marketing? You know, content marketing agencies or software vendors sending content about how you, too can learn to do content marketing? Add this to what I get from brands doing content marketing, and my inbox seems like […]
Also posted in Advertising, Agency Insight, Guest Blog, Marketing | Tagged , | Leave a comment

FDA Targets Online Pharmacies

By Melanie Sena, Pharmaceutical Technology. FDA, in partnership with other federal and international agencies, has  taken action against websites that sell potentially dangerous, unapproved prescription drugs to US consumers. FDA and the US Customs and Border Protection (CBP) also conducted examinations at US-based international mail facilities, where many packages containing prescription drugs enter the US, […]
Also posted in Events, Regulatory | Tagged , , , | Leave a comment

Obamacare's "Unacceptable" Rx Copays

by Tom Norton We are now approaching the six month point in the implementation of the new Obamacare program. It’s senseless to go into the good, bad and ugly of this new program. While much of the concept continues to be thrashed about in the political arena, in terms of actual medical results the truth […]
Also posted in Biotech, Guest Blog, healthcare, Legal, Market Access, Strategy | Tagged , , , , , , , | 2 Comments

Paying for the Future of Medicine

Is the hallmark of innovation higher drug prices? The three leading justifications for sticker-shocking drug prices in the US, from the biopharma perspective, are: 1) it costs a lot to bring a drug to market;* 2) drugs – even very expensive ones – are cheaper in the long run since they prevent complications, hospitalizations and […]
Also posted in Biotech, FDA, healthcare, Manufacturing, Market Access, pricing, R&D, Regulatory, Technology | Tagged , , , , , , | 1 Comment

Eight Ingredients for a Successful Oncology Drug Development Recipe

by Matthew Cook and Sebastien Morisot In light of the risks and challenges inherent in the development of oncologics, some biopharma companies are beginning to question whether oncology remains an attractive therapeutic area in which to invest limited research, development, and commercialization resources.
Also posted in Agency Insight, Biotech, Europe, FDA, Gene therapy, Guest Blog, Market Access, Orphan Drugs, pricing, R&D, Regulatory, Sales | Tagged , , | Leave a comment
  • Categories

  • Meta